venBio Partners LLC reported 7 positions worth $519.38M for the quarter ended Jun 30, 2026, up 85.1% on the prior quarter. It opened 2 new positions, added to 1, trimmed 1 and exited 1. Its largest holding is Pharvaris N.V. at 30.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| ARTV Artiva Biotherapeutics, Inc. | -531.3K | $3.42M | 1.22% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHVS Pharvaris N.V. | Healthcare | 4.64M | $160.57M | 30.92% | +4,126 | +0.1% | Added | 7.85% |
| 2 | PBLS Parabilis Medicines, Inc. | Healthcare | 5.27M | $144.15M | 27.75% | +5.27M | – | New | 4.32% |
| 3 | ALMS Alumis Inc. | Healthcare | 4.53M | $127.43M | 24.53% | 0 | 0.0% | Unchanged | 3.55% |
| 4 | ACHV Achieve Life Sciences, Inc. | Healthcare | 5.91M | $38.62M | 7.44% | +5.91M | – | New | 5.76% |
| 5 | ALXO Alx Oncology Holdings Inc | Healthcare | 12.88M | $26.67M | 5.14% | 0 | 0.0% | Unchanged | 9.32% |
| 6 | HRMY Harmony Biosciences Holdings, Inc. | Healthcare | 472.2K | $17.19M | 3.31% | -17.0K | -3.5% | Reduced | 0.81% |
| 7 | LYEL Lyell Immunopharma, Inc. | Healthcare | 337.7K | $4.74M | 0.914% | 0 | 0.0% | Unchanged | 1.44% |
Tip. Select a row to see that position’s full history at venBio Partners.
As of its Q2 2026 13F filing, venBio Partners LLC’s five largest positions were Pharvaris N.V. (PHVS) at 30.9%, Parabilis Medicines, Inc. (PBLS) at 27.8%, Alumis Inc. (ALMS) at 24.5%, Achieve Life Sciences, Inc. (ACHV) at 7.4%, Alx Oncology Holdings Inc (ALXO) at 5.1% of the reported portfolio.
venBio Partners LLC reported a 13F portfolio worth $519.38M across 7 positions for Q2 2026. That is up 85.1% from the previous quarter.
Its largest purchases by value were Parabilis Medicines, Inc. ($144.15M), Achieve Life Sciences, Inc. ($38.62M), Pharvaris N.V. ($142.68K). It opened 2 new positions.
Its largest sales by value were Artiva Biotherapeutics, Inc. ($3.42M), Harmony Biosciences Holdings, Inc. ($618.97K). It exited 1 positions entirely.
From the Form 13F-HR reports venBio Partners LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.